Acepix Biosciences

Acepix Biosciences, founded in 2015 and based in Cambridge, USA, is a private, revenue-generating company operating in the research tools and services sector. Its core business revolves around providing critical biospecimens—including its proprietary A-FLX FFPE cell pellets, high-RNA-quality human tissues, and animal tissue arrays—alongside a suite of histopathology and biomarker discovery services. The company leverages its biobank networks and proprietary technologies to serve as a key supplier of quality control and research materials, primarily for drug and diagnostic developers in the pharmaceutical and biotech industries. With over 7,000 projects completed, it has established a track record as a specialized service provider in the translational research space.

Proprietary A-FLX™ technology for producing consistent FFPE cell pellets; High RNA Quality FFPE tissue processing; Biomarker Cell Line Explorer software; Integrated histology and AI-powered digital pathology services.

Acepix competes in the specialized biospecimen and histopathology services market against larger global CROs (e.g., Labcorp, Charles River) and biospecimen providers (e.g., BioIVT, Discovery Life Sciences). Its differentiation lies in its proprietary A-FLX cell pellet technology and focus on high-RNA-quality FFPE tissues, targeting a niche of clients requiring premium, well-characterized controls for critical assay development and validation.